Compare
iTonic Holdings Ltd vs Guided Therapeutics Inc vs Nexalin Technology, Inc. vs ADM Tronics Unlimited, Inc.
| Latest fiscal year | iTonic Holdings Ltd ITOC | Guided Therapeutics Inc GTHP | Nexalin Technology, Inc. NXL | ADM Tronics Unlimited, Inc. ADMT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $523.0K | $767.0K | $301.6K | $3.35M |
| Revenue growth (YoY) | +16.7% | n/m | +78.8% | +4.7% |
| Gross margin | 62.6% | 74.4% | 79.7% | 40.5% |
| Operating margin | -991.7% | -309.3% | n/m | -4.8% |
| Net margin | -974.7% | -416.7% | n/m | -3.0% |
| Net income | -$5.10M | -$3.20M | -$8.22M | -$100.4K |
| EPS (Diluted) | -$0.32 | -$0.04 | -$0.50 | $0.00 |
| Operating cash flow | -$3.23M | -$1.07M | -$4.96M | -$124.1K |
| Free cash flow | -$3.24M | -$1.07M | n/a | n/a |
| Cash & equivalents | $1.49M | n/a | $654.8K | $255.7K |
| Total assets | $9.10M | $1.32M | $4.64M | $1.83M |
| Total liabilities | $969.8K | $7.33M | $887.3K | $1.26M |
| Shareholders' equity | $6.12M | -$6.01M | $3.75M | $571.0K |
| Return on year-end equity | -83.3% | n/a | -219.4% | -17.6% |
| Shares outstanding | n/a | 86.15M | 19.19M | 67.59M |
Revenue, most recent five fiscal years
| Fiscal year | iTonic Holdings Ltd | Guided Therapeutics Inc | Nexalin Technology, Inc. | ADM Tronics Unlimited, Inc. |
|---|---|---|---|---|
| Latest | $523.0K Ended 2025-12-31 | $767.0K Ended 2025-12-31 | $301.6K Ended 2025-12-31 | $3.35M Ended 2026-03-31 |
| 1 year earlier | $448.2K Ended 2024-12-31 | $7.0K Ended 2024-12-31 | $168.7K Ended 2024-12-31 | $3.20M Ended 2025-03-31 |
| 2 years earlier | $628.6K Ended 2023-12-31 | $98.0K Ended 2023-12-31 | $110.7K Ended 2023-12-31 | $2.97M Ended 2024-03-31 |
| 3 years earlier | $679.8K Ended 2022-12-31 | $13.0K Ended 2022-12-31 | $1.32M Ended 2022-12-31 | $3.68M Ended 2023-03-31 |
| 4 years earlier | n/a | $81.0K Ended 2021-12-31 | $144.1K Ended 2021-12-31 | $3.21M Ended 2022-03-31 |